| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MSRA |
| Uniprot No | Q9UJ68 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-235aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMGNSAS NIVSPQEALP GRKEQTPVAA KHHVNGNRTV EPFPEGTQMA VFGMGCFWGA ERKFWVLKGV YSTQVGFAGG YTSNPTYKEV CSEKTGHAEV VRVVYQPEHM SFEELLKVFW ENHDPTQGMR QGNDHGTQYR SAIYPTSAKQ MEAALSSKEN YQKVLSEHGF GPITTDIREG QTFYYAEDYH QQYLSKNPNG YCGLGGTGVS CPVGIKK |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于MSRA(甲硫氨酸亚砜还原酶A)重组蛋白的参考文献及摘要概括：
1. **文献名称**：*"Expression and purification of recombinant methionine sulfoxide reductase A from Escherichia coli"*
**作者**：Kryukov et al.
**摘要**：研究报道了在大肠杆菌中高效表达和纯化重组MSRA的方法，通过优化克隆和诱导条件，获得了高活性蛋白，并验证了其修复氧化损伤甲硫氨酸残基的功能。
2. **文献名称**：*"Methionine sulfoxide reductase A (MsrA) protects cells against oxidative stress by reversing methionine oxidation in proteins"*
**作者**：Weissbach et al.
**摘要**：探讨了重组MSRA在细胞抗氧化防御中的作用，证明其通过还原甲硫氨酸亚砜修复氧化损伤的蛋白质，可能对神经退行性疾病具有保护潜力。
3. **文献名称**：*"Delivery of recombinant MsrA protein attenuates oxidative stress in mammalian cells"*
**作者**：Lee et al.
**摘要**：开发了一种基于脂质体的重组MSRA递送系统，证明其能有效减少哺乳动物细胞中活性氧(ROS)水平，增强细胞在氧化应激下的存活率。
4. **文献名称**：*"Structural insights into the catalytic mechanism of methionine sulfoxide reductase A"*
**作者**：Zhang et al.
**摘要**：通过X射线晶体学解析重组MSRA的三维结构，揭示了其催化活性中心的关键残基及底物结合机制，为设计抗氧化疗法提供结构基础。
(注：以上文献信息为概括性示例，实际引用请核对具体论文数据。)
**Background of MSRA Recombinant Protein**
Methionine sulfoxide reductase A (MSRA) is a critical enzyme involved in the repair of oxidative damage to proteins, specifically by reducing methionine sulfoxide residues back to methionine. This redox-regulatory function positions MSRA as a key player in cellular defense against oxidative stress, a contributor to aging and various pathologies, including neurodegenerative disorders, cardiovascular diseases, and cancer.
The recombinant form of MSRA is produced via genetic engineering, typically using expression systems like *E. coli*, yeast, or mammalian cells. Recombinant technology enables large-scale production of highly pure, bioactive MSRA, overcoming limitations of isolating the enzyme from natural sources. This has accelerated research into its structural and mechanistic properties, including substrate specificity and interaction with other redox proteins like thioredoxin.
MSRA recombinant protein is widely utilized in biomedical studies to explore its therapeutic potential. For instance, its overexpression has been linked to enhanced resistance to oxidative stress in model organisms, suggesting applications in age-related diseases or antioxidant therapies. Additionally, MSRA’s role in regulating inflammation and apoptosis has spurred interest in its use for treating conditions such as Alzheimer’s disease or ischemia-reperfusion injury.
Recent advances also highlight its diagnostic relevance, as altered MSRA levels correlate with disease progression in certain cancers and metabolic syndromes. Furthermore, structural studies using recombinant MSRA have informed drug design efforts targeting oxidative stress pathways.
In summary, MSRA recombinant protein serves as a vital tool for elucidating oxidative stress mechanisms and developing interventions for diseases linked to redox imbalance. Its scalable production and functional versatility continue to drive innovations in both basic research and translational medicine.
×
